These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 17047284

  • 1. Enhanced platelet adhesion and aggregation by endothelial cell-derived unusually large multimers of von Willebrand factor.
    Kumar RA, Moake JL, Nolasco L, Bergeron AL, Sun C, Dong JF, McIntire LV.
    Biorheology; 2006; 43(5):681-91. PubMed ID: 17047284
    [Abstract] [Full Text] [Related]

  • 2. Thrombotic thrombocytopenic purpura.
    Moake JL.
    Thromb Haemost; 1995 Jul; 74(1):240-5. PubMed ID: 8578465
    [Abstract] [Full Text] [Related]

  • 3. Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy.
    Byrnes JJ, Moake JL.
    Clin Haematol; 1986 May; 15(2):413-42. PubMed ID: 3524932
    [Abstract] [Full Text] [Related]

  • 4. A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow.
    Galbusera M, Remuzzi A, Benigni A, Rossi C, Remuzzi G.
    Am J Kidney Dis; 2000 Oct; 36(4):695-702. PubMed ID: 11007670
    [Abstract] [Full Text] [Related]

  • 5. [Biology of von Willebrand factor].
    Girma JP.
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S143-8. PubMed ID: 17373215
    [Abstract] [Full Text] [Related]

  • 6. Adhesion of platelets to purified solid-phase von Willebrand factor: effects of wall shear rate, ADP, thrombin, and ristocetin.
    Olson JD, Zaleski A, Herrmann D, Flood PA.
    J Lab Clin Med; 1989 Jul; 114(1):6-18. PubMed ID: 2786916
    [Abstract] [Full Text] [Related]

  • 7. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
    Moake JL, McPherson PD.
    Am J Med; 1989 Sep; 87(3N):9N-15N. PubMed ID: 2486537
    [Abstract] [Full Text] [Related]

  • 8. Characterisation of a monoclonal antibody to von Willebrand factor as a potent inhibitor of ristocetin-mediated platelet interaction and platelet adhesion.
    Jorieux S, de Romeuf C, Samor B, Goudemand M, Mazurier C.
    Thromb Haemost; 1987 Jun 03; 57(3):278-82. PubMed ID: 3116700
    [Abstract] [Full Text] [Related]

  • 9. Abnormally large von Willebrand factor multimers in Henoch-Schönlein purpura.
    Casonato A, Pontara E, Bertomoro A, Ossi E, Vincenti M, Girolami A, Borsatti A, Bertaglia G.
    Am J Hematol; 1996 Jan 03; 51(1):7-11. PubMed ID: 8571941
    [Abstract] [Full Text] [Related]

  • 10. Increased neonatal platelet deposition on subendothelium under flow conditions: the role of plasma von Willebrand factor.
    Shenkman B, Linder N, Savion N, Tamarin I, Dardik R, Kennet G, German B, Varon D.
    Pediatr Res; 1999 Feb 03; 45(2):270-5. PubMed ID: 10022601
    [Abstract] [Full Text] [Related]

  • 11. Thrombotic thrombocytopenic purpura: understanding a disease no longer rare.
    Moake JL, Chow TW.
    Am J Med Sci; 1998 Aug 03; 316(2):105-19. PubMed ID: 9704664
    [Abstract] [Full Text] [Related]

  • 12. von Willebrand factor in the pathophysiology of thrombotic thrombocytopenic purpura.
    Moake JL.
    Clin Lab Sci; 1998 Aug 03; 11(6):362-4. PubMed ID: 10345504
    [Abstract] [Full Text] [Related]

  • 13. Loss of high-molecular-weight von Willebrand factor multimers mainly affects platelet aggregation in patients with aortic stenosis.
    Panzer S, Badr Eslam R, Schneller A, Kaider A, Koren D, Eichelberger B, Rosenhek R, Budde U, Lang IM.
    Thromb Haemost; 2010 Feb 03; 103(2):408-14. PubMed ID: 20024494
    [Abstract] [Full Text] [Related]

  • 14. Shear stress and the role of high molecular weight von Willebrand factor multimers in thrombus formation.
    López JA, Dong JF.
    Blood Coagul Fibrinolysis; 2005 Apr 03; 16 Suppl 1():S11-6. PubMed ID: 15849521
    [Abstract] [Full Text] [Related]

  • 15. Endothelial microparticles induce formation of platelet aggregates via a von Willebrand factor/ristocetin dependent pathway, rendering them resistant to dissociation.
    Jy W, Jimenez JJ, Mauro LM, Horstman LL, Cheng P, Ahn ER, Bidot CJ, Ahn YS.
    J Thromb Haemost; 2005 Jun 03; 3(6):1301-8. PubMed ID: 15946221
    [Abstract] [Full Text] [Related]

  • 16. Generation and breakdown of soluble ultralarge von Willebrand factor multimers.
    Turner N, Nolasco L, Moake J.
    Semin Thromb Hemost; 2012 Feb 03; 38(1):38-46. PubMed ID: 22314602
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
    Mayr FB, Knöbl P, Jilma B, Siller-Matula JM, Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P.
    Transfusion; 2010 May 03; 50(5):1079-87. PubMed ID: 20070617
    [Abstract] [Full Text] [Related]

  • 19. On the mechanism of plasmin-induced aggregation of human platelets: implication of secreted von Willebrand factor.
    Rabhi-Sabile S, de Romeuf C, Pidard D.
    Thromb Haemost; 1998 Jun 03; 79(6):1191-8. PubMed ID: 9657447
    [Abstract] [Full Text] [Related]

  • 20. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A, Hermans C, Berneman Z, Schroyens W, Deckmyn H, Michiels JJ.
    Acta Haematol; 2009 Jun 03; 121(2-3):71-84. PubMed ID: 19506352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.